Can a targeted drug make chemotherapy work again for ovarian cancer?
NCT ID NCT03287271
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is investigating whether adding an experimental drug called defactinib to standard chemotherapy (paclitaxel and carboplatin) can help treat ovarian cancer that has become resistant to platinum-based chemotherapy. The study includes people with recurrent ovarian, fallopian tube, or primary peritoneal cancer that progressed within six months of their last platinum treatment. The goal is to see if this combination is safe, tolerable, and effective in shrinking tumors or slowing disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- defactinib (VS-6063) combined with paclitaxel and carboplatin chemotherapy
- What this could lead to
- If successful, this could offer a new treatment option for ovarian cancer that has stopped responding to standard platinum-based chemotherapy, potentially extending the time before the disease progresses.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The drug combination may cause significant side effects, and the results may not apply to all patients with ovarian cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Diego
San Diego, California, 92023, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?